| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
5,366,000 |
| Market
Cap: |
7.14(M) |
| Last
Volume: |
140,704 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.506 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing cancer immunotherapeutics for a range of cancer indications. Co.'s product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Co.'s primary product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms tumor 1 protein, which is present in 20 or more cancer types. NPS is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 expressing cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
9,806 |
| Total Sell Value |
$0 |
$0 |
$0 |
$25,516 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Scheinberg David A |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,582 |
|
- |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
117,225 |
|
- |
|
| Francomano Robert |
Chief Commercial Officer |
• – – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,918 |
|
- |
|
| Van Nostrand Robert L |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,400 |
|
- |
|
| Burns John Thomas |
CFO |
• – – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
47,000 |
101,927 |
|
- |
|
| Varian John |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,400 |
|
- |
|
| Kalin Katherine Bach |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
8,500 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
159,000 |
376,421 |
|
- |
|
| Wasman Jane |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,400 |
|
- |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2023-12-06 |
4 |
D |
$1.08 |
$4,449 |
D/D |
(4,119) |
82,225 |
|
- |
|
| Burns John Thomas |
CFO |
• – – |
2023-12-06 |
4 |
D |
$1.08 |
$3,163 |
D/D |
(2,929) |
54,927 |
|
- |
|
| Francomano Robert |
Chief Commercial Officer |
• – – |
2023-12-06 |
4 |
D |
$1.08 |
$1,169 |
D/D |
(1,082) |
20,918 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2023-12-06 |
4 |
D |
$1.08 |
$13,249 |
D/D |
(12,268) |
217,421 |
|
- |
|
| Wasman Jane |
Director |
– • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
4,400 |
|
- |
|
| Francomano Robert |
Chief Commercial Officer |
• – – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
|
- |
|
| Burns John Thomas |
CFO |
• – – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
49,347 |
|
- |
|
| Van Nostrand Robert L |
Director |
– • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
4,400 |
|
- |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
76,344 |
|
- |
|
| Kalin Katherine Bach |
Director |
– • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
58,000 |
219,689 |
|
- |
|
| Varian John |
Director |
– • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
4,400 |
|
- |
|
| Scheinberg David A |
Director |
– • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
4,582 |
|
- |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2022-12-05 |
4 |
S |
$2.59 |
$5,576 |
D/D |
(2,153) |
56,344 |
|
34% |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2022-12-05 |
4 |
S |
$2.61 |
$16,938 |
D/D |
(6,494) |
161,689 |
|
34% |
|
| Burns John Thomas |
Senior VP, Finance & CAO |
• – – |
2022-12-05 |
4 |
S |
$2.59 |
$3,002 |
D/D |
(1,159) |
29,347 |
|
34% |
|
90 Records found
|
|
Page 1 of 4 |
|
|
0.02 (1.48%) 
